Alterations of the WNT7A gene in clear cell renal cell carcinomas

PLoS One. 2012;7(10):e47012. doi: 10.1371/journal.pone.0047012. Epub 2012 Oct 8.

Abstract

WNT7A (wingless-type MMTV integration site family, member 7A) is a known tumor suppressor gene of non-small cell lung carcinomas (NSCLC) and is frequently inactivated due to CpG-island hypermethylation in human cancers. The members of WNT family are involved in cell signaling and play crucial roles in cancer development. In the present work hypermethylation of the WNT7A gene was detected in 66% (29/44) of analyzed clear cell renal cell carcinomas (RCCs) using methyl-specific PCR (MSP). Moreover, bisulfite sequencing confirmed intensive hypermethylation of the 5'-CpG island of the WNT7A gene. Methylation analysis revealed positive correlations between tumor stage, Fuhrman nuclear grade and WNT7A hypermethylation. Additionally, restoration of WNT7A gene expression in the A498 cell line by 5-aza-2'-deoxycytidine treatment confirmed a direct contribution of hypermethylation in silencing of the WNT7A gene. High frequency of loss of heterozygosity (LOH) was demonstrated on chromosome 3p25 in regions surrounding the WNT7A gene. The frequent down-regulation of WNT7A gene expression was detected in 88% (15/17) of clear cell RCCs. We have also shown that the WNT7A gene possesses tumor suppression function by colony-formation and cell proliferation assays in RCC cell lines. In summary, the WNT7A gene is inactivated by genetic/epigenetic alterations in clear cell RCC and demonstrates tumor suppressor properties.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Azacitidine / analogs & derivatives
  • Azacitidine / pharmacology
  • Carcinoma, Renal Cell / genetics*
  • Carcinoma, Renal Cell / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • DNA Methylation / drug effects
  • DNA Methylation / genetics
  • Decitabine
  • Down-Regulation / drug effects
  • Down-Regulation / genetics
  • Epigenesis, Genetic / drug effects
  • Epigenesis, Genetic / genetics
  • Female
  • Genetic Markers / genetics
  • Humans
  • Loss of Heterozygosity / drug effects
  • Loss of Heterozygosity / genetics
  • Male
  • Microsatellite Repeats / genetics
  • Middle Aged
  • Wnt Proteins / genetics*
  • Young Adult

Substances

  • Genetic Markers
  • WNT7A protein, human
  • Wnt Proteins
  • Decitabine
  • Azacitidine

Grants and funding

This work was supported by the State Fond of Fundamental Research (grant No F46/457-2011). E.R. Zabarovsky was supported by research grants from the Swedish Cancer Society, the Swedish Institute and the Swedish Research Council. A. Kondratov was partially supported by a travel fellowship from EACR for research in the MTC department of Karolinska Institute (Sweden, Stockholm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.